← Leaderboards
Randy F. Sweis
University Of Chicago
$850,676
Attributed
$850,676
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $212.7K · FY2018–21$250K$187.5K$125K$62.5K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$850,676 · 1
By mechanism
K08$850,676 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Thomas F Gajewski$23,743,716
- Minoli A Perera$7,566,589
- David O Meltzer$45,291,714
- Andrea C King$19,745,933
- Dezheng Huo$7,892,516
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsCombined Modality TherapyAntigensAntibodiesAnti-Pd-1Clustered Regularly Interspaced Short Palindromic RepeatsBeta CateninBioinformaticsBiological ModelsBladderAnti-Tumor Immune ResponseCancer Cell LineCancer GenomicsBaseCancer PatientCarcinomaCareer DevelopmentCd8-Positive T-LymphocytesCheckpoint TherapyChicagoClinical DevelopmentClinical EfficacyClinical PracticeCoupled
Grant awards (4)
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer$212,669
K08 · FY2021 · CA · contact PI
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer$212,669
K08 · FY2020 · CA · contact PI
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer$212,669
K08 · FY2019 · CA · contact PI
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer$212,669
K08 · FY2018 · CA · contact PI